Journal of Cutaneous Immunology and Allergy最新文献

筛选
英文 中文
A case of ruptured Baker's cyst induced by nivolumab and ipilimumab 纳武单抗联合伊匹单抗致贝克囊肿破裂1例
IF 1
Journal of Cutaneous Immunology and Allergy Pub Date : 2023-03-09 DOI: 10.1002/cia2.12290
Marie Kubo MD, Tomomitsu Miyagaki MD, PhD, Hiroyuki Ohashi MD, Arisa Kishi MD, Kaoru Miyano MD, Tatsuro Okano MD, PhD, Mayuko Muto MD, Sora Takeuchi MD, PhD, Mitsuru Imamura MD, PhD, Takafumi Kadono MD, PhD
{"title":"A case of ruptured Baker's cyst induced by nivolumab and ipilimumab","authors":"Marie Kubo MD,&nbsp;Tomomitsu Miyagaki MD, PhD,&nbsp;Hiroyuki Ohashi MD,&nbsp;Arisa Kishi MD,&nbsp;Kaoru Miyano MD,&nbsp;Tatsuro Okano MD, PhD,&nbsp;Mayuko Muto MD,&nbsp;Sora Takeuchi MD, PhD,&nbsp;Mitsuru Imamura MD, PhD,&nbsp;Takafumi Kadono MD, PhD","doi":"10.1002/cia2.12290","DOIUrl":"10.1002/cia2.12290","url":null,"abstract":"<p>Here, we presented the rare case of ruptured Baker's cyst induced by immune checkpoint inhibitors (ICIs). The history of more than one immune-related adverse event (irAE) like our case was reported to be associated with a more persistent course of arthritis. Mild persistent inflammation without subjective symptoms might exist after first ICI therapy followed by ruptured Baker's cyst. It is important to pay attention to potential musculoskeletal irAEs in ICI-treated patients with multiple irAEs.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12290","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44564593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kikuchi-Fujimoto disease presenting with papular lesions on the elbows and knees 菊口-藤本病表现为肘部和膝盖的丘疹性病变
IF 1
Journal of Cutaneous Immunology and Allergy Pub Date : 2023-03-09 DOI: 10.1002/cia2.12300
Izumi Takei MD, Kazuhiro Kawai MD, PhD, Mihoko Yamazaki MD, PhD
{"title":"Kikuchi-Fujimoto disease presenting with papular lesions on the elbows and knees","authors":"Izumi Takei MD,&nbsp;Kazuhiro Kawai MD, PhD,&nbsp;Mihoko Yamazaki MD, PhD","doi":"10.1002/cia2.12300","DOIUrl":"10.1002/cia2.12300","url":null,"abstract":"<p>Kikuchi-Fujimoto disease is a self-limited febrile lymphadenitis of unknown etiology, possibly associated with cutaneous lesions. We report a case of Kikuchi-Fujimoto disease presenting with papular lesions limited to the elbows and knees. The skin biopsy specimen showed spongiosis and pseudo-Pautrier abscesses in addition to the typical histopathological findings of Kikuchi-Fujimoto disease. Although necrosis was not observed in the lymph node biopsy specimen, histopathological and immunohistochemical findings were consistent with Kikuchi-Fujimoto disease in the proliferating phase.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12300","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46083828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Instantly evaluating bacterial infections on skin ulcers in an Asian population using a fluorescence-emitting device 使用荧光发射装置即时评估亚洲人群皮肤溃疡的细菌感染
IF 1
Journal of Cutaneous Immunology and Allergy Pub Date : 2023-03-02 DOI: 10.1002/cia2.12293
Yu Kurokami MD, Yukiho Kurosaki MD, Chigusa Yamashita MD, Kazunori Yokoi MD, Kyoko Tonomura MD, Eiji Kiyohara MD, PhD, Yosuke Ishitsuka MD, PhD, Manabu Fujimoto MD, PhD, Atsushi Tanemura MD, PhD
{"title":"Instantly evaluating bacterial infections on skin ulcers in an Asian population using a fluorescence-emitting device","authors":"Yu Kurokami MD,&nbsp;Yukiho Kurosaki MD,&nbsp;Chigusa Yamashita MD,&nbsp;Kazunori Yokoi MD,&nbsp;Kyoko Tonomura MD,&nbsp;Eiji Kiyohara MD, PhD,&nbsp;Yosuke Ishitsuka MD, PhD,&nbsp;Manabu Fujimoto MD, PhD,&nbsp;Atsushi Tanemura MD, PhD","doi":"10.1002/cia2.12293","DOIUrl":"10.1002/cia2.12293","url":null,"abstract":"<p>MolecuLight i:X® is a handy instrument capable of visualizing the bacterial adhesion over 10,000 CFU/g by recognizing porphyrin and pyoverdine as fluorescence. We took a total of 55 clinical photographs and fluorescence images (20 cases) from May 2021 to December 2021, after which the correlation between fluorescence observation and culture results was investigated. In addition, the course of fluorescent and ulcer status was shown in representative cases. The results suppose that MolecuLight i:X® is in real-time use and would be helpful in determining the range of collection of bacterial cultures as well as in judging therapeutic necessity for intractable skin ulcers.</p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12293","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43060890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Detection of Cpy-2, Fks and Erg 11 Genes in Fungal Isolates from Sars Cov-2 Individual in Ibadan, Oyo State, Nigeria 尼日利亚奥约州伊巴丹地区Sars Cov-2个体真菌分离株Cpy-2、Fks和Erg - 11基因的检测
IF 1
Journal of Cutaneous Immunology and Allergy Pub Date : 2023-03-01 DOI: 10.37191/mapsci-2582-6549-4(1)-042
Bamigbola F
{"title":"Detection of Cpy-2, Fks and Erg 11 Genes in Fungal Isolates from Sars Cov-2 Individual in Ibadan, Oyo State, Nigeria","authors":"Bamigbola F","doi":"10.37191/mapsci-2582-6549-4(1)-042","DOIUrl":"https://doi.org/10.37191/mapsci-2582-6549-4(1)-042","url":null,"abstract":"A considerable number of fungal strains have developed resistant to various available antifungal agents due to CPY, FKS and or ERG11 genes complicating coinfection cases of SAR COV-2 virus. Therefore, this study sought to isolate, identify azole and polyene resistant genes in fungal pathogens isolated from confirmed SARS-CoV-2 individual in Oyo State, Nigeria. Nasopharyngeal samples were collected from symptomatic and asymptomatic SARS-CoV-2 infected adult from September, 2020 to April, 2021. Samples were cultured on Sabouraud Dextrose Agar at room and at 37 oC temperature for 7days. Identification of the fungal isolates were performed using MALDITOF MS VITEK. Antifungal Susceptibility Testing (AFST) were performed using Kirby bauer disc diffusion method. The resistant genes in fugal isolates were determined by Polymerase Chain Reaction with specific primers and resistant genes were amplified using agarose gel electrophoresis. Out of 63(15.8%) fungal isolates recorded from 400 samples collected, Asipergillus flavus 11(17.5%), Aspergillus niger 9(14.3%), Candida albicans 7(11.1%), Candida guillermondii 2(3.2%), Candida parapsilosis 2(3.2%), Candida famata 2(3.2%), Candida tropicalis 5(7.9%) and Lodderomyces elongisporus 25(39%) having highest frequency were recorded respectively. Nystatin (84.1%) had highest susceptibility testing and Ketoconazole (39.7%) had the least phenotypically. 10 (52.6%) isolates possessed CPY gene, 8(42.1%) isolates carried FKS gene, 9(47.4%) isolates had ERG11 gene molecularly.","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84293645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Monkeypox Outbreak - Case Report 猴痘爆发-病例报告
IF 1
Journal of Cutaneous Immunology and Allergy Pub Date : 2023-03-01 DOI: 10.37191/mapsci-2582-6549-4(1)-041
H. B. Reinfeld
{"title":"Monkeypox Outbreak - Case Report","authors":"H. B. Reinfeld","doi":"10.37191/mapsci-2582-6549-4(1)-041","DOIUrl":"https://doi.org/10.37191/mapsci-2582-6549-4(1)-041","url":null,"abstract":"A zoonotic disease, monkeypox virus disease, appeared once in the west and central Africa. On July 23, 2022, the WHO designated the current monkeypox epidemic a public health emergency of worldwide concern in the context of the COVID-19 pandemic. The rapidly growing number of confirmed cases may endanger international society. According to current epidemiological statistics, the high frequency of human-to-human transmission might lead to more epidemics, particularly among males who have sex with men. Despite some therapeutic effects of presently used medications in the clinic, the development of antiviral treatments and vaccines against the monkeypox virus is urgent.","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74163490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Herculean Task of Tedros 泰德罗斯的艰巨任务
IF 1
Journal of Cutaneous Immunology and Allergy Pub Date : 2023-03-01 DOI: 10.37191/mapsci-2582-6549-4(1)-040
R. Maes
{"title":"The Herculean Task of Tedros","authors":"R. Maes","doi":"10.37191/mapsci-2582-6549-4(1)-040","DOIUrl":"https://doi.org/10.37191/mapsci-2582-6549-4(1)-040","url":null,"abstract":"The WHO was created in 1950 with the prime assignment to fight tuberculosis. To this end, it was granted immunity against any prosecution. The French state immediately exploited this advantage to impose the BCG vaccine developed by the Pasteur institute, although this vaccine was known, by both the Pasteur institute and the WHO, to be deficient. It was poorly attenuated and some of its strains favor the spread of TB. The BCG also favors the spread of leprosy. The WHO knew this and nevertheless supported this fraud. It banned serological tests and imposed an expensive antigen- detection test, the Xpert/Rif test, in 2011. This test was rapidly demonstrated to be peppered with severe deficiencies, which were ignored by the treatment action group (TAG) and the WHO. Both insisted on its use while systematically denigrating the serological tests that this antigen-test was supposed to replace. The result of the use of this ill-functioning test was the spread of multi-drug resistant strains of TB. Serological tests monitor the immune status of infected patients: it allows the detection of those patients prone to convert as well as the immune status of patients under therapy. Those who do not respond to current treatment are therewith detected. A shameful demand of financial contribution by those countries that suffered most from the mismanagement of TB by well–endowed nations is currently underway.","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73364601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinically and radiologically successful treatment of spondylitis by guselkumab in a patient with pustulotic arthro-osteitis guselkumab在脓疱性关节炎患者中成功治疗脊柱炎的临床和放射学研究
IF 1
Journal of Cutaneous Immunology and Allergy Pub Date : 2023-02-07 DOI: 10.1002/cia2.12299
Natsumi Ikumi MD, Hideki Fujita MD, PhD
{"title":"Clinically and radiologically successful treatment of spondylitis by guselkumab in a patient with pustulotic arthro-osteitis","authors":"Natsumi Ikumi MD,&nbsp;Hideki Fujita MD, PhD","doi":"10.1002/cia2.12299","DOIUrl":"10.1002/cia2.12299","url":null,"abstract":"<p>A 29-year-old Japanese woman presented with a 6-month history of pustular eruptions on the palms and soles. She also suffered from pain and stiffness in the anterior chest and the lumbar spine for 3 months, which were treated with loxoprofen. Although she had no history of rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis, she was diagnosed with endometrial uterine cancer 3 years before. After treatment with surgery and chemotherapy, she experienced no recurrence of the tumor. She had neither focal infection nor history of smoking. At presentation, the patient had erythema with scales and pustules on the palms and soles. Palmoplantar pustulosis (PPP) area and severity index (PPPASI) was 16.8. Serologically, C-reactive protein and rheumatoid factor were negative. Lumbar magnetic resonance imaging (MRI) revealed bone marrow edema in L4 and L5 under T2-weighted condition, corroborating the presence of spondylitis (Figure 1A). <sup>99m</sup>Tc bone scintigraphy showed increased uptakes in the right clavicle and sternoclavicular joint and the lumbar spines (Figure 1B). A diagnosis of PPP with pustulotic arthro-osteitis (PAO) was made. Three-month treatment with topical betamethasone butyrate propionate and maxacalcitol resulted in partial improvement of skin symptoms, and PPPASI decreased to 7.9 (Figure 1C). On the other hand, pain in the back and anterior chest was persistent. Her Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) remained as high as 4.8. Because of insufficient improvement of skin symptoms and intractable back pain, treatment with anti-interleukin-23p19 subunit monoclonal antibody guselkumab was initiated. After 6-month guselkumab therapy, back pain visual analogue scale improved to 3 compared to 6 at the initiation of the treatment. In addition, BASDAI decreased to 4. Follow-up lumbar MRI demonstrated remarkable reduction of bone marrow edema in the vertebral bodies of L4 and L5 using short TI inversion recovery image (Figure 1D). Bone scintigraphy also confirmed decreased uptakes in the lumbar spines and the right clavicular region (Figure 1E). On the other hand, her anterior chest pain did not ameliorate even after the treatment. During the 6-month treatment, skin symptoms completely disappeared (Figure 1F).</p><p>The efficacy of guselkumab for PPP has been established,<span><sup>1, 2</sup></span> and it is approved for PPP in Japan. However, very limited information is available on the efficacy of this drug for PAO.<span><sup>3</sup></span> In particular, its effectiveness for spondylitis in PAO is largely unknown. We have recently reported that guselkumab improves joint pain of PAO patients as a whole.<span><sup>4</sup></span> In a PPP clinical trial, 52-week guselkumab treatment showed beneficial outcomes for MRI scores as well as EQ-5D pain/discomfort scores in PPP patients with PAO, in which the spine, sacroiliac joint, and peripheral joints were considered together.<span><sup>3</sup></span> It","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12299","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47479592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Refractory Kimura's disease accompanied with prurigo responding to dupilumab administration: A case report 杜匹单抗治疗难治性木村病伴瘙痒1例
IF 1
Journal of Cutaneous Immunology and Allergy Pub Date : 2023-02-02 DOI: 10.1002/cia2.12298
Fumie Fukami MD, Yuta Koike MD, PhD, Hiroyuki Murota MD, PhD
{"title":"Refractory Kimura's disease accompanied with prurigo responding to dupilumab administration: A case report","authors":"Fumie Fukami MD,&nbsp;Yuta Koike MD, PhD,&nbsp;Hiroyuki Murota MD, PhD","doi":"10.1002/cia2.12298","DOIUrl":"10.1002/cia2.12298","url":null,"abstract":"<p>Kimura's disease is refractory and sometimes has prurigo as a comorbidity. This report shows a case of Kimura's disease accompanied by prurigo and successfully treated both with dupilumab. Dupilumab might be considered for Kimura's disease with prurigo, which is resistant to conventional treatments.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12298","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45073471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Skin manifestations in children with inborn errors of immunity in a tertiary care hospital in Iran 伊朗一家三级护理医院先天性免疫缺陷儿童的皮肤表现
IF 1
Journal of Cutaneous Immunology and Allergy Pub Date : 2023-01-31 DOI: 10.1002/cia2.12296
Zahra Salehi Shahrbabaki MD, Zahra Chavoshzadeh MD, Fahimeh Abdollahimajd MD, Samin sharafian MD, Mahnaz Jamee MD, Anastasia Bondarenko MD, Tolue Mahdavi MD
{"title":"Skin manifestations in children with inborn errors of immunity in a tertiary care hospital in Iran","authors":"Zahra Salehi Shahrbabaki MD,&nbsp;Zahra Chavoshzadeh MD,&nbsp;Fahimeh Abdollahimajd MD,&nbsp;Samin sharafian MD,&nbsp;Mahnaz Jamee MD,&nbsp;Anastasia Bondarenko MD,&nbsp;Tolue Mahdavi MD","doi":"10.1002/cia2.12296","DOIUrl":"10.1002/cia2.12296","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Inborn errors of immunity (IEIs) are monogenic diseases of the immune system. Despite the increasing genetic advancements, the diagnosis of IEIs still lean on clinical diagnosis. Dermatological manifestations are observed in a large number of IEI patients and can lead to proper approach and prompt intervention.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This cross-sectional study was carried out between 2018 and 2020 on IEIs at a Children's tertiary care center in Tehran, Iran. Demographic details and age at onset of symptoms of IEI were recorded.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall, 212 patients were included. Cutaneous findings were reported in 95 (44.8%) patients, and 61 of 95 (64.2%) reported skin lesions as the first clinical presentation. Skin infection (69, 72.6%) was the most frequent cutaneous manifestation, followed by eczematous rash (24, 25%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Skin manifestations are a common feature in IEI patients and are readily recognizable by healthcare providers. This study tried to provide information on prognostic consequences.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12296","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44693107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Earlier continuous administration of mepolizumab for eosinophilic granulomatosis with polyangiitis based on cutaneous findings 根据皮肤检查结果,早期连续给药美波珠单抗治疗嗜酸性肉芽肿伴多血管炎
IF 1
Journal of Cutaneous Immunology and Allergy Pub Date : 2023-01-29 DOI: 10.1002/cia2.12295
Takaharu Ikeda MD, PhD, Toshiro Komatsu MD, Kae Yokoyama MD, Tamihiro Kawakami MD, PhD
{"title":"Earlier continuous administration of mepolizumab for eosinophilic granulomatosis with polyangiitis based on cutaneous findings","authors":"Takaharu Ikeda MD, PhD,&nbsp;Toshiro Komatsu MD,&nbsp;Kae Yokoyama MD,&nbsp;Tamihiro Kawakami MD, PhD","doi":"10.1002/cia2.12295","DOIUrl":"10.1002/cia2.12295","url":null,"abstract":"<p>Treatment of eosinophilic granulomatosis with polyangiitis (EGPA) remains a challenge because currently available therapies, corticosteroids, and immunomodulators, do not always control symptoms and are often associated with significant morbidity and relapse. We previously proposed that the initial cutaneous clinical and histopathologic findings based on skin biopsy and peripheral blood findings, as hallmark manifestations of EGPA, could prompt dermatologists to consider this diagnosis at an earlier stage.<span><sup>1</sup></span> Based on these cutaneous findings, we also reported that earlier adjunct administration of mepolizumab and intravenous immunoglobulin therapy (IVIG) led to significant improvement in EGPA symptoms.<span><sup>2</sup></span> Since those initial reports, we have been able to maintain good control of the disease, allowing us to taper their prednisolone dosage without any negative impact on the improvement of these symptoms or any significant adverse effects related to the drugs during a 3-year follow-up.</p><p>A 55-year-old man presented with erythematous nodules and livedo racemosa with purpura on his leg edema. There were clinical signs of mononeuritis multiplex as evidence of peripheral neurologic involvement. Microscopic examination of the indurated nodules revealed necrotizing vasculitis in the lower dermis and subcutaneous fat. There was a predominance of eosinophil infiltration into the dermis around the vascular walls and nerve fiber. He had been treated with oral prednisolone and intravenous cyclophosphamide pulse therapy (IVCY). The therapy did not resolve his symptoms, including the associated multiple mononeuritis. We administered IVIG, 400 mg/kg for 5 days, and mepolizumab 300 mg subcutaneously every 4 weeks to address concerns of exacerbation of complications such as peripheral neuropathy. The symptoms gradually improved, with resolution of the peripheral eosinophilia and normalized IgE levels. Azathioprine was additionally administered from the 6th month as prednisolone was tapered smoothly. To date, he has not developed any additional vasculitis symptoms during the 3-year follow-up (Figure 1A).</p><p>A 30-year-old woman presented with slightly purpuric skin lesions on her lower extremities. Nerve conduction tests revealed a mononeuritis multiplex on her lower extremities. Microscopic examination of skin biopsy specimens obtained from the purpura revealed leukocytoclastic vasculitis. There was a predominance of eosinophils infiltrating the dermis around the nerve fiber. We applied an adjunct combination therapy of IVIG and mepolizumab. After two courses of this adjunct therapy, the cutaneous manifestations, as well as the arthritis and mononeuritis multiplex had been completely resolved along with the normalization of peripheral eosinophilia, without any remarkable adverse effects related to prednisone such as opportunistic infections. Prednisolone was subsequently tapered smoothly. After 3 years, there ha","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12295","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48273876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信